Chromosomal instability may predict patients that will benefit from colorectal cancer drug

(RCSI) Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).
Source: EurekAlert! - Biology - Category: Biology Source Type: news